Updated: Oct 15
Medically reviewed by ChinaCureLink Team
Table of Content
Why This Case Matters
Mr. Chen's(alias) five-year journey with poorly differentiated squamous cell lung cancer shows how interventional oncology can play an important role when tumor-related airway obstruction or bleeding becomes an immediate threat to life. His treatment included local tumor ablation, including microwave ablation for lung cancer in China, as well as image-guided vascular intervention at critical points in his disease course.
For international patients facing similarly complex lung cancer complications, ChinaCureLink can coordinate medical-record review, specialist assessment, treatment planning, and access to an appropriate oncology center in China.
Key Takeaways |
|
Patient Background
Mr. Chen's(alias) cancer journey began in March 2020, when he developed sudden hemoptysis and required emergency interventional embolization at a local hospital. A subsequent biopsy identified poorly differentiated squamous cell lung carcinoma.
Over the following years, his medical history became extensive. His treatment record included particle implantation, tracheal stenting, local tumor ablation and arterial perfusion chemotherapy.
The most serious respiratory crisis came in February 2022. Mr. Chen developed severe breathing difficulties and was urgently assessed in Guangzhou. Bronchoscopy showed that tumor tissue had completely blocked both main bronchi, leaving very little room for normal airflow.
The immediate priority was therefore not simply long-term cancer control. His airway had to be reopened.
The Care Team and Approach
The interventional oncology team was led by Dr. Wei, a pseudonym used here for the treating physician.
In February 2022, the team used bronchoscopy to identify the obstructing tumor tissue and performed microwave ablation to remove the lesions blocking the airways. The procedure lasted nearly five hours because of the extent and complexity of the obstruction.
Microwave ablation uses a thin probe to deliver electromagnetic energy into targeted tissue. The resulting heat produces localized tumor-cell destruction. In this case, the goal was highly focused: remove enough obstructing tumor tissue to restore ventilation through both main bronchi.
The team later used a different interventional strategy when Mr. Chen developed recurrent hemoptysis. Angiography identified the vessels responsible for the active bleeding, allowing the physicians to deliver treatment directly through the arterial circulation and then embolize the relevant vessels.
The source describes this approach as combining targeted drug delivery with interruption of the tumor's blood supply.
Treatment Timeline/ Process
March 2020 — Diagnosis Begins
Mr. Chen developed sudden hemoptysis.
He underwent emergency interventional embolization at a local hospital.
A postoperative biopsy confirmed poorly differentiated squamous cell lung carcinoma.
His subsequent treatment course included several interventional procedures, including particle implantation, tracheal stenting, local ablation and arterial perfusion chemotherapy.
February 2022 — Emergency Airway Treatment
Severe respiratory distress required urgent hospital treatment.
Bronchoscopy showed complete obstruction of both main bronchi by tumor tissue.
The interventional team performed bronchoscopically guided microwave ablation.
The procedure lasted nearly five hours.
Obstructing tumor tissue was progressively removed until ventilation was restored to both lungs.
His oxygen saturation subsequently increased as the airways reopened.
September 2025 — Temporary Stabilization
A previously placed main tracheal stent became displaced and was removed.
His condition stabilized temporarily.
November 2025 — Second Life-or-Death Crisis
Intermittent hemoptysis returned in early November.
Imaging identified active bleeding involving the intercostal-bronchial common trunk and right internal thoracic artery.
At approximately 11 p.m. on November 10, the team began an emergency DSA-guided procedure.
Angiography was performed to identify the bleeding vessels.
The right bronchial artery and bilateral bronchial arteries underwent superselective perfusion and embolization.
The right internal thoracic artery was also treated with superselective embolization.
The procedure finished in the early hours of the following morning.
His hemoptysis was effectively controlled and his oxygen saturation returned to safe levels.
Outcome
Mr. Chen's(alias) latest emergency intervention successfully controlled the recurrent hemoptysis and restored his oxygen saturation to a safe range.
His five-year treatment course demonstrates the role of interventional oncology in managing serious complications of lung cancer. In his case, microwave ablation was used to relieve life-threatening airway obstruction, while later arterial intervention was used to control tumor-associated bleeding.
The case does not establish that his lung cancer was cured or in complete remission. His treatment remained focused on managing the cancer and its potentially life-threatening complications.
How ChinaCureLink Can Help International Patients to Access This Treatment
International patients with advanced lung cancer can face difficult decisions when standard treatment options become limited or when complications such as airway obstruction or tumor-related bleeding require highly specialized intervention.
ChinaCureLink can help international patients explore whether interventional oncology in China is appropriate for their individual situation. The process can include:
Medical-record review — Your imaging, pathology, treatment history and current condition are reviewed before travel.
Specialist matching — We identify an appropriate oncology and interventional treatment team based on the patient's diagnosis and clinical needs.
Treatment planning — The Chinese medical team assesses whether procedures such as microwave ablation, vascular intervention, embolization or other localized treatments have a role.
Travel and hospital coordination — ChinaCureLink can coordinate appointments, treatment scheduling and practical arrangements for international patients.
Ongoing communication — We help patients and families understand the proposed treatment pathway and communicate with the treating team throughout the process.
Every patient's treatment plan is individualized. The techniques used in this case are not automatically suitable for every patient with lung cancer.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Can international lung cancer patients travel to China for microwave ablation?
Yes, international patients can seek assessment for interventional cancer treatment in China. Suitability depends on the tumor's location, size, anatomy, previous treatments, overall health and the specific clinical objective. A specialist review of medical records and imaging should take place before travel.
Can microwave ablation be used when lung cancer is blocking the airway?
Microwave ablation can be used in selected circumstances to destroy targeted tumor tissue. When a tumor is obstructing a major airway, the treatment approach depends on the exact location and extent of the obstruction and may involve bronchoscopy, ablation, stenting or other interventional techniques.
How can I find out whether this type of treatment is suitable for my lung cancer?
Start with your pathology report, recent CT or PET-CT scans, bronchoscopy reports and previous treatment records. ChinaCureLink can arrange a medical-record review with an appropriate Chinese specialist and determine whether an interventional treatment pathway should be considered.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This case study is for educational purposes only and does not constitute medical advice, diagnosis or a treatment recommendation. Lung cancer treatment must be determined by qualified oncology specialists based on the individual patient's pathology, imaging, disease stage, overall health and previous treatments. Patients should seek advice from their treating oncologist before making decisions about travel or cancer treatment.
